Skip to main content
SpringerLink
Log in

The need for early markers in Alzheimer’s disease

  • Chapter
Early Markers in Parkinson’s and Alzheimer’s Diseases

Part of the book series: New Vistas in Drug Research ((DRUG RESEARCH,volume 1))

Summary

Currently, there are no definitive early markers for Alzheimer’s disease (AD) or senile dementia of the Alzheimer type (SDAT). Nonetheless, there are some interesting marker candidates under evaluation. Several examples of candidate markers are considered in this review, including some biochemical, genetic, pharmacological, neuroimaging, and clinical measures. These examples are chosen to illustrate some aspects of an ideal marker, as well as the needs for such markers in different areas of AD and SDAT research and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aigner TG, Mitchell SJ, Aggleton JP, DeLong MR, Struble RG, Price DL,Wenk GL, Mishkin M (1987) Effects of scopolamine and physostigmine on recognition memory in monkeys with ibotenic-acid lesions of the nucleus basalis of Meynert. Psychopharmacology 92: 292–300

    CAS  Google Scholar 

  • Barclay L (1988) Differential diagnosis of dementing diseases. Age 11: 19–22

    Article  Google Scholar 

  • Beal MF, Growdon JH, Mazurek MF, Martin JB (1986) CSF somatostatinlike immunoreactivity in dementia. Neurology 36: 294–297

    PubMed  CAS  Google Scholar 

  • Berg L (1985) Does Alzheimer’s disease represent an exaggeration of normal aging? Arch Neurol 42: 737–739

    Article  PubMed  CAS  Google Scholar 

  • Brayne C, Calloway P (1988) Normal ageing, impaired cognitive function, and senile dementia of the Alzheimer’s type: a continuum? Lancet is 1265–1267

    Google Scholar 

  • Brody JA (1982) An epidemiologist views senile dementia: facts and fragments. Am J Epidemiol 115: 155–162

    PubMed  CAS  Google Scholar 

  • Chakravarti A, Slaugenhaupt SA, Zubenko GS (1989) Inheritance pattern of platelet membrane fluidity in Alzheimer’s disease. Am J Hum Genet 44: 799–805

    PubMed  CAS  Google Scholar 

  • Clark DC, Clayton PS, Andreasen NC, Lewis C, Fawcett J, Scheftner WAK (1985) Intellectual functioning and abstraction ability in major affective disorders. Compr Psychiatry 26: 313–325

    Article  PubMed  CAS  Google Scholar 

  • Cutler NR (1988 a) Utility of biologic markers in the evaluation and diagnosis of Alzheimer’s disease. Brain Dysfunction 1: 12–31

    Google Scholar 

  • Cutler NR (1988 b) Recent advances in the development of ante-mortem diagnostic markers for Alzheimer’s disease. Curr Opin Psychiatry 1: 462–467

    Article  Google Scholar 

  • Davies P (1988) Neurochemical studies: an update on Alzheimer’s disease. J Clin Psychiatry 49 [Suppl 5]: 23–28

    PubMed  CAS  Google Scholar 

  • Davies P, Maloney AJR (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet ii: 1403–1405

    Google Scholar 

  • Davis KL, Davidson M, Yang RK, Davis BM, Siever LJ, Mohs RC, Ryan T, Coccaro E, Bierer L, Targum SD (1988) CSF somatostatin in Alzheimer’s disease, depressed patients, and control subjects. Biol Psychiatry 24: 710–712

    Article  PubMed  CAS  Google Scholar 

  • Drachman DA, Leavitt J (1974) Human memory and the cholinergic system. Arch Neurol 30: 113–121

    Article  PubMed  CAS  Google Scholar 

  • Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y (1987) Cholinergic-dependent cognitive deficits in Parkinson’s disease. Ann Neurol 22: 26–30

    Article  PubMed  CAS  Google Scholar 

  • Friedland RP, Brun A, Budinger TF (1985 a) Pathological and positron emis- sion tomographic correlations in Alzheimer’s disease. Lancet is 228

    Google Scholar 

  • Friedland RP, Budinger TF, Koss E, Ober BA (1985 b) Alzheimer’s disease: anterio-posterior and lateral hemispheric alterations in cortical glucose utilization. Neurosci Lett 53: 235–240

    Article  PubMed  CAS  Google Scholar 

  • Friedland RP, Koss E, Haxby JV, Grady CL, Luxenberg J, Schapiro MB, Kaye J (1988) Alzheimer’s disease: clinical and biological heterogeneity. Ann Intern Med 109: 298–311

    PubMed  CAS  Google Scholar 

  • Funsch D, Sunderland T, Lawlor BA, Molchan SE, Mellow AM, Tariot PN, Hill JL, Murphy DL (1989) Platelet MAO activity in Alzheimer patients, older depressives, and age-matched controls. Society of Biological Psychiatry, San Francisco, CA (Abstract )

    Google Scholar 

  • Gottfries CG (1985) Alzheimer’s disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology 86: 245–252

    Article  PubMed  CAS  Google Scholar 

  • Hachinski VC, Lassen NA, Marshall J (1974) Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet ii: 207–210

    Article  Google Scholar 

  • Hollander E, Mohs RC, Davis KL (1986) Antemortem markers of Alzheimer’s disease. Neurobiol Aging 7: 367–387

    Article  PubMed  CAS  Google Scholar 

  • Holman BL, Gibson RE, Hill TC, Eckelman WC, Albert M, Reba RC (1985) Muscarinic acetylcholine receptors in Alzheimer’s disease: in vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography. JAMA 254: 3063–3066

    Article  PubMed  CAS  Google Scholar 

  • Kuhl DE, Small GW, Riege WH, Fujikawa DG, Metter EJ, Benson DF, Ashford JW, Mazziotta JC, Maltese A, Dorsey DA (1987) Abnormal PET-FDG scans in early Alzheimer’s disease. J Nucl Med 28: 645 (Abstract)

    Google Scholar 

  • Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL (1989 a) Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer’s disease: a controlled study. Arch Gen Psychiatry 46: 542–549

    Article  PubMed  CAS  Google Scholar 

  • Lawlor BA, Sunderland T, Mellow AM, Hill JL, Newhouse PA, Murphy DL (1989 b) A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects. Biol Psychiatry 25: 679–686

    Article  PubMed  CAS  Google Scholar 

  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDSADRDA work group. Neurology 34: 939–944

    PubMed  CAS  Google Scholar 

  • Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988) Intravenous nicotine in Alzheimer’s disease: a pilot study. Psychopharmacology 95: 171–75

    Article  PubMed  CAS  Google Scholar 

  • Perry E (1988) Acetylcholine and Alzheimer’s disease. Br J Psychiatry 152: 737–740

    Article  PubMed  CAS  Google Scholar 

  • Post F (1975) Dementia, depression, and pseudo-dementia. In: Benson DF, Blumer D (eds) Psychiatric aspects of neurologic disease. Grune and Stratton, New York, pp 99–120

    Google Scholar 

  • Prohovnik I, Mayeux R, Sackeim HA, Smith G, Stern Y, Alderson PO (1988) Cerebral perfusion as a diagnostic marker of early Alzheimer’s disease. Neurology 38: 931–937

    PubMed  CAS  Google Scholar 

  • Reifler BV, Larson E, Hanley R (1982) Coexistence of cognitive impairment and depression in geriatric outpatients. Am J Psychiatry 139: 623–626

    PubMed  CAS  Google Scholar 

  • Risberg J, Gustafson L (1983) Xe cerebral blood flow in dementia and in neuropsychiatry research. In: Magistretti P (ed) Functional radionuclide imaging of the brain. Raven Press, New York

    Google Scholar 

  • Ron MA, Toone BK, Garralda ME, Lishman WA (1979) Diagnostic accuracy in presenile dementia. Br J Psychiatry 134: 161–168

    Article  PubMed  CAS  Google Scholar 

  • Roy BF, Sunderland T, Dauphin MM, Goodman A, Frazier JS, Murphy DL, Morihisa JM (in press) Human antibody to nerve growth factor: a preliminary study with implications for Alzheimer’s disease. Ann Neurol

    Google Scholar 

  • Schneider LS, Severson JA, Chui HC, Pollock VE, Sloane RB, Fredrickson ER (1988) Platelet tritiated imipramine binding and MAO activity in Alzheimer’s disease patients with agitation and delusions. Psychiatry Res 25: 311–322

    Article  PubMed  CAS  Google Scholar 

  • Sunderland T, Rubinow DR, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL (1987) CSF somatostatin in patients with Alzheimer’s disease, older depressed patients, and age-matched control subjects. Am J Psychiatry 144: 1313–1316

    PubMed  CAS  Google Scholar 

  • Sunderland T, Tariot PN, Newhouse PA (1988) Differential responsivity of mood, behaviour, and cognition to cholinergic agents in elderly neuropsychiatrie populations. Brain Res Rev 13: 371–389

    Article  Google Scholar 

  • Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH (1989) Clock drawing in Alzheimer’s disease: a novel measure of dementia severity. J Am Geriatr Soc 37: 725–729

    PubMed  CAS  Google Scholar 

  • Tabaton M, Whitehouse PJ, Perry G, Davies P, Autilio-Gambetti L, Gambetti P (1988) Alz 50 recognizes abnormal filaments in Alzheimer’s disease and progressive supranuclear palsy. Ann Neurol 24: 407–413

    Article  PubMed  CAS  Google Scholar 

  • Tanzi RE, St George-Hyslop PH, Gusella JF (1989) Molecular genetic approaches to Alzheimer’s disease. Trends Neurosci 12: 152–158

    Article  PubMed  CAS  Google Scholar 

  • Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL, Weingartner H (1988) Multiple-dose arecoline infusions in Alzheimer’s disease. Arch Gen Psychiatry 45: 901–905

    Article  PubMed  CAS  Google Scholar 

  • Thal L (1988) Dementia update: diagnosis and neuropsychiatric aspects. J Clin Psychiatry 49 [Suppl 5]: 5–7

    PubMed  Google Scholar 

  • Thienhaus OJ, Hartford JT, Skelly MF, Bosmann HB (1985) Biologic markers in Alzheimer’s disease. J Am Geriatr Soc 33: 715–726

    PubMed  CAS  Google Scholar 

  • Wade JPH, Mirsen TR, Hachinski VC, Fisman M, Lau C, Merskey H (1987) The clinical diagnosis of Alzheimer’s disease. Arch Neurol 44: 24–29

    Article  PubMed  CAS  Google Scholar 

  • Wells CE (1979) Pseudodementia. Am J Psychiatry 136: 895–900

    CAS  Google Scholar 

  • Weinberger DR, Gibson RE, Coppola R, Jones DW, Berman KF, Braun AR, Zeeberg BR, Sunderland T (1989) 123IodoQNB SPECT in Alzheimer’s and Pick’s diseases. American Psychiatric Association, San Francisco, CA (Abstract )

    Google Scholar 

  • Wolozin B, Davies P (1987) Alzheimer-related neuronal protein A 68: specificity and distribution. Ann Neurol 22: 521–526

    Article  PubMed  CAS  Google Scholar 

  • Wolozin BL, Pruchnicki A, Dickson DW, Davies P (1986) A neuronal antigen in the brains of Alzheimer patients. Science 232: 648–650

    Article  PubMed  CAS  Google Scholar 

  • Zubenko GS, Cohen BM, Boller F, Malinakova I, Keefe N, Chojnacki B (1987) Platelet membrane abnormality in Alzheimer’s disease. Ann Neurol 22: 237–244

    Article  PubMed  CAS  Google Scholar 

  • Zubenko GS, Huff FJ, Beyer J, Auerbach J, Teply I (1988) Familial risk of dementia associated with a biologic subtype of Alzheimer’s disease. Arch Gen Psychiatry 45: 889–893

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD, USA

    D. L. Murphy & T. Sunderland

Authors
  1. D. L. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Sunderland
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Farmitalia Carlo Erba, R & D, Via Imbonati 24, I-20159, Milan, Italy

    Philippe Dostert , Margherita Strolin Benedetti  & Romeo Roncucci ,  & 

  2. Clinical Neurochemistry, Department of Psychiatry, University of Würzburg, Füchsleinstrasse 15, D-W-8700, Würzburg, Federal Republic of Germany

    Peter Riederer

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag/Wien

About this chapter

Cite this chapter

Murphy, D.L., Sunderland, T. (1990). The need for early markers in Alzheimer’s disease. In: Dostert, P., Riederer, P., Strolin Benedetti, M., Roncucci, R. (eds) Early Markers in Parkinson’s and Alzheimer’s Diseases. New Vistas in Drug Research, vol 1. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9098-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9098-2_14

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-9100-2

  • Online ISBN: 978-3-7091-9098-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation